HRP20191808T1 - Mutanti tumorsko-selektivnih adenovirusa e1a i e1b - Google Patents
Mutanti tumorsko-selektivnih adenovirusa e1a i e1b Download PDFInfo
- Publication number
- HRP20191808T1 HRP20191808T1 HRP20191808TT HRP20191808T HRP20191808T1 HR P20191808 T1 HRP20191808 T1 HR P20191808T1 HR P20191808T T HRP20191808T T HR P20191808TT HR P20191808 T HRP20191808 T HR P20191808T HR P20191808 T1 HRP20191808 T1 HR P20191808T1
- Authority
- HR
- Croatia
- Prior art keywords
- recombinant adenovirus
- pea3
- site
- nucleotides
- adenovirus according
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 title 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 claims 14
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 108700019146 Transgenes Proteins 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000000717 retained effect Effects 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108700019961 Neoplasm Genes Proteins 0.000 claims 1
- 102000048850 Neoplasm Genes Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Rekombinantni adenovirus koji sadrži DNK sekvencu umetnutu u mjesto umetanja E1b-19K, pri čemu se navedeno mjesto umetanja nalazi između početnog mjesta Elb-19K i početnog mjesta E1b 55K i pri čemu navedeno E1b-19K mjesto umetanja sadrži brisanje najmanje 100 baznih parova, nadalje pri čemu gen Elb-55K nije poremećen, i pri čemu je navedena DNK sekvenca sekvenca koja kodira transgene, gene karcinoma ili mutiranu DNK sekvencu.
2. Rekombinantni adenovirus u skladu s patentnim zahtjevom 1, pri čemu navedeno mjesto umetanja sadrži brisanje 202 baznih parova nastavno na navedeno početno mjesto Elb-19K.
3. Rekombinantni adenovirus u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni transgen gen za supresiju tumora, gen toksina, gen citokina, gen za aktiviranje lijeka ili apoptotički gen.
4. Rekombinantni adenovirus u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni transgen faktor nekroze tumora, kras ili njegov funkcionalni dio.
5. Rekombinantni adenovirus u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni transgen mutirana sekvenca p53.
6. Rekombinantni adenovirus u skladu s bilo kojim patentnim zahtjevom 1-5, pri čemu rekombinantni adenovirus nadalje sadrži modificiranu regulatornu sekvencu E1a, pri čemu je najmanje jedno mjesto vezivanja Pea3 ili njegov funkcionalni dio, izbrisan, pri čemu je funkcionalni dio najmanje jednog mjesta vezivanja Pea3 je dio mjesta vezivanja koji, kada je izbrisan smanjuje afinitet vezanja mjesta vezivanja Pea3.
7. Rekombinantni adenovirus u skladu s patentnim zahtjevom 6, pri čemu se najmanje jedan nukleotid zadržava u rasponu od -305 do -141.
8. Rekombinantni adenovirus u skladu s patentnim zahtjevom 6 ili 7, pri čemu je najmanje jedan Pea3 II, Pea3 III, Pea4 IV i Pea3 V ili njegov funkcionalni dio, izbrisan, opcionalno pri čemu predmet odabran između a), b) i c) je izbrisan:
a) najmanje jedan Pea3 II i Pea3 III ili njegov funkcionalni dio;
b) Pea3II ili njegov funkcionalni dio i Pea3 III ili njegov funkcionalni dio; i
c) najmanje jedan Pea3 IV i Pea3 V ili njegov funkcionalni dio.
9. Rekombinantni adenovirus u skladu s bilo kojim patentnim zahtjevom 6-8, pri čemu se Pea3 I ili njegov funkcionalni dio, zadržava, opcionalno pri čemu se najmanje jedno mjesto vezivanja E2F ili njegov funkcionalni dio, zadržava, pri čemu funkcionalni dio najmanje jednog mjesta vezivanja E2F je dio mjesta vezivanja koje, kada je izbrisano, smanjuje afinitet vezanja mjesta vezivanja E2F.
10. Rekombinantni adenovirus u skladu s patentnim zahtjevom 6, pri čemu navedeni rekombinantni adenovirus sadrži brisanje nukleotida koji se nalaze uzvodno od mjesta inicijacije E1a, pri čemu je brisanje odabrano između:
a) nukleotida od -393 do -304;
b) nukleotida od -305 do -255;
c) nukleotida od -270 do -240;
d) nukleotida od -299 do -293;
e) nukleotida od -270 do -265; ili
f) nukleotida od -299 do -293 i nukleotida -270 do -265.
11. Farmaceutski pripravak koji sadrži farmaceutski prihvatljivu pomoćnu tvar i rekombinantni adenovirus u skladu s bilo kojim patentnim zahtjevom 1-10.
12. Farmaceutski pripravak koji sadrži farmaceutski prihvatljivu pomoćnu tvar i rekombinantni adenovirus u skladu s bilo kojim patentnim zahtjevom 1-10 za uporabu u liječenju karcinoma.
13. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 12, pri čemu je farmaceutski pripravak za kontaktiranje ciljane stanice.
14. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 13, pri čemu je navedena ciljana stanica neoplastična stanica ili normalna stanica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682209P | 2009-03-02 | 2009-03-02 | |
| EP15182086.7A EP3029144B1 (en) | 2009-03-02 | 2010-03-02 | Tumor-selective adenovirus e1a and e1b mutants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191808T1 true HRP20191808T1 (hr) | 2019-12-27 |
Family
ID=42710189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151396T HRP20151396T1 (hr) | 2009-03-02 | 2015-12-21 | Mutanti adenovirusa e1a i e1b selektivni za tumore |
| HRP20191808TT HRP20191808T1 (hr) | 2009-03-02 | 2019-10-03 | Mutanti tumorsko-selektivnih adenovirusa e1a i e1b |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151396T HRP20151396T1 (hr) | 2009-03-02 | 2015-12-21 | Mutanti adenovirusa e1a i e1b selektivni za tumore |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9073980B2 (hr) |
| EP (4) | EP3591059B1 (hr) |
| JP (5) | JP6072414B2 (hr) |
| KR (4) | KR102150027B1 (hr) |
| CY (1) | CY1122385T1 (hr) |
| DK (2) | DK2403951T3 (hr) |
| ES (2) | ES2557812T3 (hr) |
| HR (2) | HRP20151396T1 (hr) |
| HU (2) | HUE046565T2 (hr) |
| LT (1) | LT3029144T (hr) |
| PL (2) | PL2403951T3 (hr) |
| PT (2) | PT3029144T (hr) |
| SI (2) | SI2403951T1 (hr) |
| SM (1) | SMT201500329B (hr) |
| WO (1) | WO2010101921A2 (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3029144T (pt) | 2009-03-02 | 2019-10-28 | Univ California | Mutantes e1a e e1b de adenovírus seletivos de tumor |
| EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| KR20240014617A (ko) * | 2016-09-27 | 2024-02-01 | 에피센트알엑스, 인코포레이티드 | 면역조정 융합 단백질 |
| CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| CA3052086A1 (en) * | 2017-01-30 | 2018-08-02 | Epicentrx, Inc. | Tumor selective tata-box and caat-box mutants |
| SG11201906973TA (en) * | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| CN111133102A (zh) * | 2017-04-10 | 2020-05-08 | 埃皮辛特瑞柯斯公司 | 生产重组病毒的方法 |
| EA201990822A1 (ru) * | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| MX2019014059A (es) * | 2017-05-24 | 2020-07-28 | Epicentrx Inc | Adenovirus antiangiogenico. |
| BR112019024813A2 (pt) * | 2017-05-26 | 2020-06-09 | Epicentrx Inc | adenovírus recombinantes portando transgenes |
| US11834492B2 (en) | 2017-09-27 | 2023-12-05 | Epicentrx, Inc. | Human IL-10 receptor alpha fusion proteins |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| CA3094329A1 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| EP3773649A4 (en) * | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| US20210205383A1 (en) * | 2018-08-31 | 2021-07-08 | Orca Therapeutics B.V. | Recombinant Replication Competent Viruses Comprising a Coding Region for Glycogen Synthase Kinase-3 (GSK3) and Methods of Killing Aberrant Cells |
| WO2021072129A2 (en) | 2019-10-08 | 2021-04-15 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| CN114262691A (zh) * | 2020-09-16 | 2022-04-01 | 杭州康万达医药科技有限公司 | 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643567A (en) | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5352775A (en) | 1991-01-16 | 1994-10-04 | The Johns Hopkins Univ. | APC gene and nucleic acid probes derived therefrom |
| JPH06509578A (ja) | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| EP0716148B1 (en) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Recombinant alphavirus vectors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| US5902925A (en) | 1996-07-01 | 1999-05-11 | Integrated Sensor Solutions | System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
| US6764674B1 (en) * | 1999-01-28 | 2004-07-20 | Onyx Pharmaceuticals Inc. | Adenovirus E1B shuttle vectors |
| EP1135514B1 (en) * | 1999-01-28 | 2009-05-13 | Onyx Pharmaceuticals, Inc. | E1b-deleted adenoviral shuttle vectors |
| WO2001083797A2 (en) * | 2000-04-28 | 2001-11-08 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| WO2002018550A1 (en) * | 2000-08-25 | 2002-03-07 | The General Hospital Corporation | Selective precipitation of viruses |
| CN1183250C (zh) * | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| GB0117198D0 (en) * | 2001-07-13 | 2001-09-05 | Btg Int Ltd | Anti-neoplastic viral agents |
| JP2005532829A (ja) * | 2002-07-18 | 2005-11-04 | インヴィトロジェン コーポレーション | 組換え部位を含むウイルスベクター |
| US20040106184A1 (en) * | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| CA2590257A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| US20100137415A1 (en) | 2007-04-20 | 2010-06-03 | Takara Bio Inc. | Vector for gene therapy |
| PT3029144T (pt) | 2009-03-02 | 2019-10-28 | Univ California | Mutantes e1a e e1b de adenovírus seletivos de tumor |
-
2010
- 2010-03-02 PT PT151820867T patent/PT3029144T/pt unknown
- 2010-03-02 JP JP2011553041A patent/JP6072414B2/ja active Active
- 2010-03-02 EP EP19171420.3A patent/EP3591059B1/en active Active
- 2010-03-02 LT LT15182086T patent/LT3029144T/lt unknown
- 2010-03-02 HU HUE15182086A patent/HUE046565T2/hu unknown
- 2010-03-02 PL PL10749205T patent/PL2403951T3/pl unknown
- 2010-03-02 ES ES10749205.0T patent/ES2557812T3/es active Active
- 2010-03-02 SI SI201031077T patent/SI2403951T1/sl unknown
- 2010-03-02 DK DK10749205.0T patent/DK2403951T3/en active
- 2010-03-02 KR KR1020197025813A patent/KR102150027B1/ko active IP Right Grant
- 2010-03-02 SI SI201031944T patent/SI3029144T1/sl unknown
- 2010-03-02 ES ES15182086T patent/ES2750305T3/es active Active
- 2010-03-02 EP EP15182086.7A patent/EP3029144B1/en active Active
- 2010-03-02 HU HUE10749205A patent/HUE026386T2/en unknown
- 2010-03-02 PL PL15182086T patent/PL3029144T3/pl unknown
- 2010-03-02 EP EP22178897.9A patent/EP4123030A1/en active Pending
- 2010-03-02 PT PT107492050T patent/PT2403951E/pt unknown
- 2010-03-02 WO PCT/US2010/025926 patent/WO2010101921A2/en active Application Filing
- 2010-03-02 KR KR1020187012031A patent/KR102020018B1/ko active IP Right Grant
- 2010-03-02 DK DK15182086.7T patent/DK3029144T3/da active
- 2010-03-02 US US13/254,825 patent/US9073980B2/en active Active
- 2010-03-02 KR KR1020117022884A patent/KR101752910B1/ko active IP Right Grant
- 2010-03-02 EP EP10749205.0A patent/EP2403951B1/en active Active
- 2010-03-02 KR KR1020177017391A patent/KR101922539B1/ko active IP Right Grant
-
2015
- 2015-05-26 US US14/722,021 patent/US20160017294A1/en not_active Abandoned
- 2015-08-12 JP JP2015159434A patent/JP6375273B2/ja active Active
- 2015-12-21 HR HRP20151396T patent/HRP20151396T1/hr unknown
- 2015-12-31 SM SM201500329T patent/SMT201500329B/it unknown
-
2018
- 2018-02-28 JP JP2018035231A patent/JP6817979B2/ja active Active
- 2018-08-08 US US16/058,886 patent/US10876097B2/en active Active
-
2019
- 2019-10-03 HR HRP20191808TT patent/HRP20191808T1/hr unknown
- 2019-10-10 CY CY20191101067T patent/CY1122385T1/el unknown
-
2020
- 2020-02-07 JP JP2020019294A patent/JP2020078326A/ja active Pending
- 2020-11-20 US US17/100,671 patent/US11618888B2/en active Active
-
2021
- 2021-09-29 JP JP2021158698A patent/JP7326396B2/ja active Active
-
2022
- 2022-11-23 US US17/993,182 patent/US20230272349A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191808T1 (hr) | Mutanti tumorsko-selektivnih adenovirusa e1a i e1b | |
| Lebedeva et al. | Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7 | |
| JP5435871B2 (ja) | Ｅ１−マイナスアデノウイルス及びその使用 | |
| AU2010219364B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor | |
| US20090099125A1 (en) | Pan cancer oncolytic vectors and methods of use thereof | |
| US20090156796A1 (en) | Metastatic colon cancer specific promoter and uses thereof | |
| JP2017534263A5 (hr) | ||
| WO1998039465A2 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
| AU2010257327C1 (en) | Adenovirus expressing genes in reverse order and use thereof | |
| JP2008526188A5 (hr) | ||
| Lin et al. | MAR characteristic motifs mediate episomal vector in CHO cells | |
| Relph et al. | Adenoviral strategies for the gene therapy of cancer | |
| EP1678193B1 (en) | Hepatocellular carcinoma specific promoter and uses thereof | |
| WO2008031331A1 (fr) | Adénovirus recombinant orienté cible coexprimant p53 et p53aip1 humains | |
| KR102167934B1 (ko) | 재조합 아데노바이러스 및 이를 포함하는 줄기세포 | |
| JP4361954B2 (ja) | アデノウィルス核酸を含有する医薬用組成物 | |
| EP1601772B1 (en) | Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same | |
| Ma et al. | E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer | |
| CA2515650A1 (en) | New adenoviruses, nucleic acids coding therefor and their use | |
| US20040171159A1 (en) | Cell-specific adenovirus vector comprising EBV-specific promoter | |
| RU2351361C2 (ru) | Новое применение аденовируса и кодирующих его нуклеиновых кислот | |
| AU2015201828B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor | |
| CN115038455A (zh) | 复制增强的溶瘤腺病毒 | |
| AU745600B2 (en) | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof | |
| WO2007003612A1 (en) | Tumor restricted oncolytic virus with improved cell transduction spectrum |